Transthyretin amyloid cardiomyopathy

Disease3 papers1 finding

Humans3

Associations

1

Deep learning AI-ECG model

upin humans1

1 study

deep learning AI-ECG model predicts transthyretin amyloid cardiomyopathy in humans (AUROC 0.84 (95% CI, 0.79-0.89)).
Humansinternal temporal validationn = 44,123
Electrocardiogram-Based Deep Learning to Prioritize Testing for Transthyretin Amyloid Cardiomyopathy · JAMA · 28 Aug 2026

Trial sponsors

Columbia University
1 trialPhase 415 people

Funding

National Heart, Lung, and Blood InstituteUS$171k1 grant since 2026

TARGET-TTR: Targeted Artificial Intelligence-Driven Screening of Transthyretin Amyloid Cardiomyopathy in the Electronic Health Record
National Heart, Lung, and Blood InstituteYale UniversityUS$171k2026–2031

Latest

5

European Heart Journal Cardiovascular ImagingHumans15 Sep

Prospective Systematic Screening for Transthyretin Amyloid Cardiomyopathy in Cardiology Inpatients With Left Ventricular Hypertrophy: the IMPACT Study

Cardiology and TherapyHumans13 Sep

Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients with Transthyretin Amyloid Cardiomyopathy

AmyloidHumans10 Sep

Frailty is a mortality risk factor in tafamidis-treated patients with transthyretin cardiac amyloidosis

JAMAHumans28 Aug

Electrocardiogram-Based Deep Learning to Prioritize Testing for Transthyretin Amyloid Cardiomyopathy

AHA Scientific Sessions 2025 AbstractReview3 Nov

Efficacy of Sodium-Glucose cotransporter 2 Inhibitors among Cardiac Amyloidosis patients: A Meta-analysis